Ovarian Cancer Clinical Trial
Clinical Pre-screening Protocol for Ovarian Cancer
Summary
The pre-screening study is established to pre-screen tumor samples from ovarian cancer patients to identify if they, at a later stage of their disease, will benefit from treatment with any investigational cancer drugs available to Oncology Venture, when these drugs are approved for future clinical studies by local authorities.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Patients with histological confirmed epithelia ovarian cancer
Relapse after 2 or more chemotherapies for ovarian cancer
FFPE tumor tissue available
Exclusion Criteria:
Other primary malignancy within the last 5 years prior to enrolment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There are 4 Locations for this study
See Locations Near You
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States
OU Health Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States More Info
Oklahoma City Oklahoma, 73104, United States More Info
Kathleen Moore, MD
Principal Investigator
Principal Investigator
Swedish Center for Research and Innovation
Seattle Washington, 98122, United States More Info
Seattle Washington, 98122, United States More Info
Fernanda Baptista Musa, MD
Principal Investigator
Principal Investigator
Beatson West of Scotland Cancer Centre
Glasgow Scotland, G12 0, United Kingdom More Info
Glasgow Scotland, G12 0, United Kingdom More Info
Ros Glasspool, MD
Principal Investigator
Principal Investigator
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
London , , United Kingdom More Info
London , , United Kingdom More Info
Rebecca Kristeleit, MD
Contact
Contact
Mai Worthington
Contact
Contact
How clear is this clinincal trial information?